Asset Details
Do you wish to reserve the book?
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Do you wish to request the book?
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
2012
Overview
Objective To determine the potential clinical and pathological significance of altered expression of interleukin 6 (IL-6) in systemic sclerosis (SSc). Methods Serum IL-6 and soluble IL-6 receptor levels were measured in patients with SSc (n=68) and healthy controls (n=15). Associations between serum IL-6 level and C reactive protein, platelet count and key clinical outcomes in SSc were explored. Expression of IL-6 in skin biopsies was also examined and western blot and reverse transcription PCRanalysis were performed using cultured dermal fibroblasts. The effect of IL-6 trans-signalling on production of extracellular matrix proteins was assessed and downstream signalling pathways were examined using pharmacological inhibitors. Results Serum IL-6 level was frequently elevated in patients with SSc, particularly in those with diffuse cutaneous SSc (dcSSc) with thrombocytosis and elevated acute phase markers. Prominent expression in the skin was observed in dermal fibroblasts, mononuclear cells and endothelial cells in patients with early dcSSc. In vitro experiments supported a potent profibrotic effect of IL-6 trans-signalling via the JAK2/STAT3 and ERK pathways. High IL-6 expression early in dcSSc appears to be associated with more severe skin involvement at 3 years and worse long-term survival than in those without elevated IL-6 levels. Conclusion Our results confirm the overexpression of IL-6 in dcSSc and support the potential of IL-6 as a surrogate marker for clinical outcome in this disease. The data also provide rationale for clinical studies targeting IL-6 trans-signalling as a potential antifibrotic therapy for SSc.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,BMJ Publishing Group,Elsevier Limited
Subject
Biological and medical sciences
/ Biopsy
/ C-Reactive Protein - analysis
/ Diseases of the osteoarticular system
/ Endothelium, Vascular - metabolism
/ Endothelium, Vascular - pathology
/ Extracellular Matrix Proteins - metabolism
/ Female
/ Humans
/ Leukocytes, Mononuclear - metabolism
/ Leukocytes, Mononuclear - pathology
/ Male
/ Proteins
/ Receptors, Interleukin-6 - blood
/ Receptors, Interleukin-6 - genetics
/ Scleroderma, Diffuse - blood
/ Scleroderma, Diffuse - mortality
/ Scleroderma, Diffuse - pathology
/ Scleroderma, Limited - blood
/ Scleroderma, Limited - mortality
/ Scleroderma, Limited - pathology
